Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 81 of 114

  1. RC 4/24 TREAT-UTI

    Istituto Gentili S.r.l.

    Urinary Tract Infections

    phase 3 small molecule active

    1 trial

  2. RC18G006

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. RCAPHM18_0018

    ISTA Pharma Limited

    Hirschsprung's disease

    phase 3 small molecule active

    1 trial

  4. RCAPHM19_0374

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

  5. REACT

    The George Institute

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  6. REC-2282

    RECURSION PHARMACEUTICALS, INC.

    Neurofibromatosis Type 2

    phase 3 small molecule terminated

    1 trial

  7. REFINE_2020

    Fondazione Telethon ETS

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. REGN10933 + REGN10987

    Regeneron UK Limited

    Healthy Participants

    phase 3 small molecule completed

    1 trial

  9. REGN1908

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule completed

    1 trial

  10. REGN1908-1909

    Regeneron UK Limited

    Allergic Rhinitis Due to Cat Allergy

    phase 3 small molecule terminated

    1 trial

  11. REGN2810

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  12. REGN2810/ipi

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  13. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  14. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  15. REGN475

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  16. REGN5713

    Regeneron UK Limited

    Allergic Rhinitis

    phase 3 small molecule completed

    2 trials

  17. REGN5713

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule active

    2 trials

  18. REGN7508

    Regeneron UK Limited

    Cancer-Associated Thrombosis (CAT)

    phase 3 small molecule active

    1 trial

  19. REGN7508

    Regeneron UK Limited

    Atrial Fibrillation (AF)

    phase 3 small molecule active

    2 trials

  20. REGN7508

    Regeneron UK Limited

    Peripheral Artery Disease (PAD)

    phase 3 small molecule active

    1 trial

  21. REGN7508

    Regeneron UK Limited

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  22. REGN7508

    Regeneron UK Limited

    Venous Thromboembolism (VTE)

    phase 3 small molecule active

    2 trials

  23. REINFORCE

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  24. REL-1017

    RELMADA THERAPEUTICS, INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  25. REMoxTB

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 3 small molecule completed

    1 trial

  26. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  27. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

  28. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  29. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  30. RGH-188-203

    Gedeon Richter Plc.

    Adolescent patient (13-17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  31. RGH-MD-20

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  32. RGX-314-3101/M23-409

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  33. RHB-102

    RedHill Biopharma

    Gastroenteritis

    phase 3 small molecule completed

    1 trial

  34. RHB-104

    RedHill Biopharma

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  35. RHB-104-04

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

  36. RHB-105

    RedHill Biopharma

    Dyspepsia

    phase 3 small molecule completed

    1 trial

  37. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  38. RHB-204

    RedHill Biopharma

    Pulmonary Mycobacterium Avium Complex Infection

    phase 3 small molecule terminated

    1 trial

  39. RIN-PF-303

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  40. RIN-PF-305

    United Therapeutics Europe Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  41. RIPH_2019_01

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

  42. RLY-2608

    Relay Therapeutics

    PIK3CA Mutation

    phase 3 small molecule active

    2 trials

  43. RLY-2608-102

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  44. RM-493-035

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  45. RMC-6236

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    1 trial

  46. RMC-6236-301

    Revolution Medicines

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  47. RMC-6236-302

    Revolution Medicines

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  48. RO5541267

    Hoffmann-La Roche

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.